Skip to main content

Market Overview

Adamas Pharmaceuticals: Q4 Earnings Insights


Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51).

Revenue of $21,010,000 rose by 28.52% from the same period last year, which beat the estimate of $20,960,000.

Looking Ahead

Adamas Pharmaceuticals Sees FY 2021 Total Operating Expenses Expenses $115M-$130M

How To Listen To The Conference Call

Date: Feb 23, 2021

Time: 04:30 PM

ET Webcast URL:


52-week high: $9.15

Company's 52-week low was at $1.90

Price action over last quarter: Up 49.86%

Company Profile

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.


Related Articles (ADMS)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings